Our Team

Cellaria unites scientific thought leaders and innovators from diverse backgrounds who share a passion for empowering the cancer research community—and accelerating the search for a cure. Through strategic collaborations, we work towards changing the landscape of cancer treatment with more personalized therapeutics. As cancer research is ever-changing and ever-evolving, we know we must remain nimble, relentless, and aligned with both the challenges of researchers and the needs of patients.

Meet Our Team

 

David Deems, CEO

Mr. Deems is a senior executive with a proven ability to commercialize and successfully launch novel technology products for the life sciences and diagnostic markets. During his career, he has developed and launched over 100 new products, in regulated and research markets, and for large public and small venture-backed companies. Most recently, Mr. Deems was the President and CEO of Xceed Molecular (now part of Axela), a Canadian company with a novel gene expression platform used by clinical laboratories for testing novel biomarkers.

He joined Xceed from Predicant Biosciences, an early-stage proteomics company working to identify protein patterns in blood for the early detection of cancer, where he was responsible for managing Predicant’s product and commercial development efforts. Prior to Predicant, David held senior management positions with several companies focused on bringing novel products successfully into the marketplace. He served as Vice President of Product Development at EXACT Sciences; CEO of Union Biometrica prior to that company’s acquisition by Harvard Biosciences; and Vice President at BD Biosciences, a division of Becton, Dickinson and Company. He holds a Bachelor’s Degree from Boston University.

 

 

 

Jake Loewenheim, Director of Business Development

Jake brings a combination of scientific knowledge and clear consultative sales processes,  to ensure that customers are able to achieve sustainable success and the best results possible throughout the drug development process. Jake spent the early portion of his career in R&D, helping to create drug development tools and conducting cancer research at the bench. Eventually, he transitioned to the commercial side where he has been involved in early stage and established Biotech companies.  His focus is on developing lasting relationships and helping clients solve difficult questions in their drug development process with new and existing technologies.

 

 

 

Dmitry Shvartsman, Director of Stem Cell Program

Dr. Dmitry (Dima) Shvartsman was born in Kharkov (Ukraine) and graduated (Ph.D. in Neurobiology, 2008) from Tel Aviv University Life Sciences Faculty (Israel), focusing his studies on the biophysical properties of the cell plasma membrane and dynamics of interactions between membrane proteins and membrane domains. He received the Long-Term Postdoctoral Fellowship from the European Molecular Biology Organization (EMBO) to conduct his postdoctoral studies in Cell and Tissue Engineering laboratory at Harvard University School of Engineering and Applied Sciences (SEAS). He continued his work at Brigham Women’s Hospital (BWH) in Boston at the field of nanoparticle formulation and targeting. After that, Dmitry joined Harvard Stem Cell Institute (HSCI) as Senior Research manager, overseeing the production of insulin-secreting beta cells from pluripotent stem cells and managing technical group within. Dmitry is married, has two children and resides in Sudbury, MA.

 

 

 

 

Connect With Us

Learn more about how Cellaria can help transform your research efficacy.

Speak to a scientist or have a general inquiry

To help us better serve you, please provide a few more pieces of information:

Subscribe to Cellaria emails

Get the latest news on Cellaria's products, services, and events.

To help us better serve you, please provide a few more pieces of information: